open access

Vol 15, No 1 (2012)
Original articles
Published online: 2012-04-24
Submitted: 2012-04-26
Accepted: 2012-04-26
Get Citation

Iodine isotope (131I) therapy for toxic nodular goitre: treatment efficacy parameters

Piotr Szumowski, Franciszek Rogowski, Saeid Abdelrazek, Agnieszka Kociura-Sawicka, Anna Sokolik-Ostasz
Nucl. Med. Rev 2012;15(1):7-13.

open access

Vol 15, No 1 (2012)
Original articles
Published online: 2012-04-24
Submitted: 2012-04-26
Accepted: 2012-04-26

Abstract

BACKGROUND: When planning radioactive iodine therapy, itfrequently happens, both in Poland and world-wide, that inadequateattention is paid to such easily measurable parametersas: 1) the serum concentration of thyrotropin (TSH) beforeadministering radioiodine, which is a key factor for extranodular(non-autonomous) iodine uptake of the thyroid gland, 2) thyroidgland iodine uptake, and 3) the effective half-life of 131I (Teff.). Theaim of the study is to evaluate the impact of the above factorson the efficacy of 131I treatment in hyperthyroid patients.

METHODS: The material consisted of 4140 patients: 2190 withautonomous toxic nodules (ATN) and 1950 with toxic multinodulargoitres (TMG). The patients were prepared for treatment insuch a way that the concentration of TSH did not exceed 0.1 mU/land Teff.< 5 days. The therapeutic activity of 131I was calculatedusing Marinelli’s formula. The selection of absorbed dose valuewas determined by the degree of suppression of extranodulartissue. Monitoring was performed every eight weeks.

RESULTS: At one year after 131I administration showed thata euthyroid status was achieved in 94%, hypothyroidism was seen observed in 3%, while persistence or recurrence of hyperthyroidismin 3% of ATN patients and, respectively, 89%, 4% and7% of TMG patients.

CONCLUSIONS: Patients with toxic nodular goitre who are to betreated with radioiodine should have the lowest possible serumconcentration of TSH. The suppression of extranodular determinesthe optimal value of absorbed dose for Marinelli’s formula.

Abstract

BACKGROUND: When planning radioactive iodine therapy, itfrequently happens, both in Poland and world-wide, that inadequateattention is paid to such easily measurable parametersas: 1) the serum concentration of thyrotropin (TSH) beforeadministering radioiodine, which is a key factor for extranodular(non-autonomous) iodine uptake of the thyroid gland, 2) thyroidgland iodine uptake, and 3) the effective half-life of 131I (Teff.). Theaim of the study is to evaluate the impact of the above factorson the efficacy of 131I treatment in hyperthyroid patients.

METHODS: The material consisted of 4140 patients: 2190 withautonomous toxic nodules (ATN) and 1950 with toxic multinodulargoitres (TMG). The patients were prepared for treatment insuch a way that the concentration of TSH did not exceed 0.1 mU/land Teff.< 5 days. The therapeutic activity of 131I was calculatedusing Marinelli’s formula. The selection of absorbed dose valuewas determined by the degree of suppression of extranodulartissue. Monitoring was performed every eight weeks.

RESULTS: At one year after 131I administration showed thata euthyroid status was achieved in 94%, hypothyroidism was seen observed in 3%, while persistence or recurrence of hyperthyroidismin 3% of ATN patients and, respectively, 89%, 4% and7% of TMG patients.

CONCLUSIONS: Patients with toxic nodular goitre who are to betreated with radioiodine should have the lowest possible serumconcentration of TSH. The suppression of extranodular determinesthe optimal value of absorbed dose for Marinelli’s formula.

Get Citation

Keywords

autonomous toxic nodules, toxic multinodular goiter, radioiodine, Marinelli’s formula

About this article
Title

Iodine isotope (131I) therapy for toxic nodular goitre: treatment efficacy parameters

Journal

Nuclear Medicine Review

Issue

Vol 15, No 1 (2012)

Pages

7-13

Published online

2012-04-24

Bibliographic record

Nucl. Med. Rev 2012;15(1):7-13.

Keywords

autonomous toxic nodules
toxic multinodular goiter
radioiodine
Marinelli’s formula

Authors

Piotr Szumowski
Franciszek Rogowski
Saeid Abdelrazek
Agnieszka Kociura-Sawicka
Anna Sokolik-Ostasz

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl